4hyf: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Structural basis and SAR for OD 270, a lead stage 1,2,4-triazole based specific Tankyrase1/2 inhibitor== | ==Structural basis and SAR for OD 270, a lead stage 1,2,4-triazole based specific Tankyrase1/2 inhibitor== | ||
<StructureSection load='4hyf' size='340' side='right' caption='[[4hyf]], [[Resolution|resolution]] 2.80Å' scene=''> | <StructureSection load='4hyf' size='340' side='right'caption='[[4hyf]], [[Resolution|resolution]] 2.80Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4hyf]] is a 3 chain structure with sequence from [ | <table><tr><td colspan='2'>[[4hyf]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4HYF OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4HYF FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1AK:4-{5-[(E)-2-{4-(2-CHLOROPHENYL)-5-[5-(METHYLSULFONYL)PYRIDIN-2-YL]-4H-1,2,4-TRIAZOL-3-YL}ETHENYL]-1,3,4-OXADIAZOL-2-YL}BENZONITRILE'>1AK</scene>, <scene name='pdbligand=NCA:NICOTINAMIDE'>NCA</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.8Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1AK:4-{5-[(E)-2-{4-(2-CHLOROPHENYL)-5-[5-(METHYLSULFONYL)PYRIDIN-2-YL]-4H-1,2,4-TRIAZOL-3-YL}ETHENYL]-1,3,4-OXADIAZOL-2-YL}BENZONITRILE'>1AK</scene>, <scene name='pdbligand=NCA:NICOTINAMIDE'>NCA</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4hyf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4hyf OCA], [https://pdbe.org/4hyf PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4hyf RCSB], [https://www.ebi.ac.uk/pdbsum/4hyf PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4hyf ProSAT]</span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | |||
</table> | </table> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/TNKS2_HUMAN TNKS2_HUMAN] Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates poly-ADP-ribosylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates poly-ADP-ribosylation of TERF1, thereby contributing to the regulation of telomere length. May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles.<ref>PMID:11802774</ref> <ref>PMID:11739745</ref> <ref>PMID:19759537</ref> <ref>PMID:21478859</ref> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 19: | Line 18: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
<div class="pdbe-citations 4hyf" style="background-color:#fffaf0;"></div> | |||
==See Also== | ==See Also== | ||
*[[Poly (ADP-ribose) polymerase|Poly (ADP-ribose) polymerase]] | *[[Poly(ADP-ribose) polymerase 3D structures|Poly(ADP-ribose) polymerase 3D structures]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
| Line 27: | Line 27: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Drewes | [[Category: Large Structures]] | ||
[[Category: Ekblad | [[Category: Drewes G]] | ||
[[Category: Holsworth | [[Category: Ekblad B]] | ||
[[Category: Krauss | [[Category: Holsworth DD]] | ||
[[Category: Morth | [[Category: Krauss S]] | ||
[[Category: Perdreau | [[Category: Morth JP]] | ||
[[Category: Schueler | [[Category: Perdreau H]] | ||
[[Category: Voronkov | [[Category: Schueler H]] | ||
[[Category: Waaler | [[Category: Voronkov A]] | ||
[[Category: Waaler J]] | |||